Hepatitis B is one of the most common infectious diseases in the world. It has been
estimated that 350 million people world‐wide are chronic hepatitis B virus (HBV) carriers …

The RNA and DNA tumor viruses have made fundamental contributions to two major areas
of cancer research. Viruses were vital, first, to the discovery and analysis of cellular growth …

Asia and Africa have previously been classified as areas of high endemicity for hepatitis B
virus (HBV), but in some countries highly effective vaccination programmes have shifted this …

The article entitled ''Interrelationship of blood transfusion, non-A, non-B hepatitis and
hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus''by Kiyosawa …

There is a wide variation of hepatitis B virus (HBV) infection in the Asia–Pacific region. The
prevalence of chronic HBV infection is lowest (< 1%) in North America, Australia and New …

Background: Familial predisposition as a risk factor for hepatocellular carcinoma (HCC) in
hepatitis B virus (HBV) carriers has not been thoroughly explored. Methods: The HCC risk …

Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world with 80% of
cases occurring in developing countries. The cancer is rapidly fatal in almost all cases with …

ContextHepatocellular carcinoma (HCC) has a male predominance and is closely related to
hepatitis B virus (HBV) infection. Hepatitis B virus vaccination was launched in 1984 in …

Although hepatitis B is an ancient disease, most of the advances in our knowledge of its
epidemiology, prevention, pathogenesis, natural history and treatment were made in the last …

The prevailing mood among immunologists and oncologists concerning immunotherapy of
cancer is still one of gloom. Indeed, as of this writing, the impact of immunotherapy on …